Inside INdiana Business is reporting that Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced a key potential treatment is moving closer to market. Taltz, which is being tested for use by patients with a type of arthritis that causes inflammation in the spine, has met its targets on two late-stage studies. Lilly says the positive results clear the way for it to submit the ankylosing spondylitis treatment for U.S. regulatory approval later this year.
Vice President of Immunology Development Lotus Mallbris says “many people with AS are either untreated or still searching for an effective treatment. By using ASAS40 as the primary endpoint in our clinical development program, we hope to establish a higher treatment bar for AS patients.”
ASAS40 means sufferers that were tested showed at least a 40 percent improvement in disease signs and symptoms. Lilly says those who took Taltz “demonstrated a statistically significant and clinically meaningful improvement” over the course of 16 weeks compared to those using placebo.
You can connect to more about the results by clicking here.